已收盘 09-19 16:00:00 美东时间
-0.290
-1.82%
The latest announcement is out from AvePoint ( ($AVPT) ). AvePoint, Inc. has an...
09-19 21:12
AvePoint ( ($AVPT) ) has provided an announcement. AvePoint, Inc. has announced...
09-19 08:12
AvePoint becomes the first B2B SaaS company listed on SGX and the first to dual-list on Nasdaq and SGX. CEO TJ Jiang highlights the listing as a key step in global expansion, especially in Singapore's tech environment. AvePoint, established in Singapore in 2009, serves as Asia headquarters and R&D hub, driving innovation in data security and governance. SGX and Nasdaq executives praised the milestone, emphasizing Singapore's role as an internatio...
09-19 01:00
AvePoint (NASDAQ:AVPT) has announced the pricing of an underwritten public offering of 13.29M shares at S$19.50 each as part of its plan to list on the Singapore Exchange Main Board. The shares are be...
09-16 20:55
AvePoint, a global leader in data security, governance, and resilience, announced the pricing of an underwritten public offering of 13,290,360 shares of its common stock at S$19.50 per share ahead of its listing on the Singapore Exchange (SGX-ST) under the symbol "AVP." Trading is expected to begin on September 19, 2025. The offering does not generate proceeds for AvePoint, aiming to create a market for its shares on the SGX-ST. The underwriters ...
09-16 12:40
-SEC Filing
09-16 05:13
AvePoint (NASDAQ:AVPT) has filed a shelf registration statement, allowing it and certain selling securityholders to offer and sell a variety of securities from time to time. The potential offerings ma...
09-16 04:35
Affirm, AvePoint, and Docebo rank in the bottom 10% for value this week—see their percentile drop and what it signals for overvaluation.
09-09 20:26
Avadel Pharmaceuticals announced new data on LUMRYZ, a once-nightly treatment for narcolepsy, to be presented at World Sleep 2025. The REFRESH real-world study highlights its efficacy for both switch and naive oxybate patients, showing improvements in excessive daytime sleepiness and narcolepsy symptoms. LUMRYZ's single bedtime dose avoids the need for waking to take a second dose, enhancing patient convenience and consistency in therapy. Additio...
09-05 12:00
今日重点评级关注:Roth Capital:维持HIVE Digital Technologies"买入"评级,目标价从6美元升至7.5美元;Craig-Hallum:维持Ranpak Hldgs"买入"评级,目标价从8美元升至10美元
08-27 08:32